Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Human E2F2 Antibodies:
anti-Mouse (Murine) E2F2 Antibodies:
anti-Rat (Rattus) E2F2 Antibodies:
Go to our pre-filtered search.
Human Monoclonal E2F2 Primary Antibody for IP, WB - ABIN967548
Lukas, Petersen, Holm, Bartek, Helin: Deregulated expression of E2F family members induces S-phase entry and overcomes p16INK4A-mediated growth suppression. in Molecular and cellular biology 1996
Show all 5 Pubmed References
Cow (Bovine) Polyclonal E2F2 Primary Antibody for WB - ABIN2777378
Iwata, Maruyama, Akagi, Hashikawa, Kanazawa, Tsuji, Nukina: Alpha-synuclein degradation by serine protease neurosin: implication for pathogenesis of synucleinopathies. in Human molecular genetics 2003
Show all 2 Pubmed References
E2F directly regulates the expression of late myogenic genes, with E2f1 (show E2F1 Antibodies) providing the major contribution compared with E2f2.
The dE2F2 protein repress the expression of buffy, the anti-apoptotic member of the Bcl-2 (show BCL2 Antibodies) family and activate the expression of an RNA-binding protein that destabilizes diap1 (show DIAPH1 Antibodies) in Drosophila.
Heterozygous mutation of mip120 (show LIN54 Antibodies) or E2f2 suppressed the binucleate cell phenotype in the peripodial epithelium of Myb (show MYB Antibodies)-null wing discs.
dE2F2, as well as the net E2F activity, which can be depleted by mutating the common cofactor, dDp (show TIMM8A Antibodies), is inhibitory for p53 (show TUBB Antibodies)-independent apoptosis.
RBF1 and RBF2 interact with different subsets of E2F proteins; this enables the RBF (show ATP5I Antibodies) proteins to regulate E2F-dependent transcription in distinct ways
cells containing dE2F2 require dE2F1 (show E2F1 Antibodies) to either prevent, or reverse, dE2F (show E2F1 Antibodies)-mediated repression
Data show that removal of p55 deregulated the expression of E2F targets that are normally repressed by dE2F2/RBF-1 and -2 complexes in a cell cycle-independent manner but had no effect on the expression of targets normally coupled with cell proliferation.
examination of linking together the Myb (show MYB Antibodies) and E2F2 complexes in higher-order assembly to specific chromosomal sites for the regulation of transcription
RBF2 has a unique function in repressing E2F-regulated differentiation markers and dE2F2 and RBF2 are required to regulate different sets of target genes in different tissues
Thease results demonstrate epigenetic regulation of gene expression by Myb (show MYB Antibodies), and E2F2-RBF (show ATP5I Antibodies) in vivo, and also provide an explanation for the ability of Mip130-null mutants to rescue the lethality of Myb (show MYB Antibodies)-null mutants in vivo.
Data indicate E2F transcription factor 2 protein (E2F2) as the direct target of miR (show MLXIP Antibodies)-31 in gastric cancer cells.
Using iterative experimental and computational analyses, the authors show physical and functional interactions between NF-kappaB (show NFKB1 Antibodies) and the E2 Factor 1 (E2F-1 (show E2F1 Antibodies)) and E2 Factor 4 (E2F-4 (show E2F4 Antibodies)) cell cycle regulators.
These results suggest that miR (show MLXIP Antibodies)-125a acts as a tumor suppressor via regulation of E2F2 expression in osteosarcoma progression, and miR (show MLXIP Antibodies)-125a may represent a novel therapeutic target for the treatment of osteosarcoma.
Accordingly, our results demonstrated that NAMPT (show NAMPT Antibodies) is a prognostic marker in melanoma, and the identificationofNAMPT-E2F2-SIRT1 (show SIRT1 Antibodies) pathway establishes another link between NAMPT (show NAMPT Antibodies) and apoptosis events in melanoma, with therapeutic implications for this deadly cancer.
Compared with patients with variant genotypes of E2F2-rs2742976 and E2F2-rs3218123, patients with common homozygous genotypes had better disease-free survival (both log-rank, P < 0.001) and lower squamous cell carcinoma of the oropharynx recurrence risk (HR, 0.4, 95% CI, 0.3-0.6 and HR, 0.3, 95% CI, 0.2-0.5, respectively) after multivariable adjustment.
Let-7b inhibits the malignant behavior of glioma cells and glioma stem-like cells via downregulation of E2F2.
In NSCLC patients, E2F2 expression was found to be significantly correlated with sex and tumor size. E2F1 (show E2F1 Antibodies) and E2F2 overexpression showed a significant association with poor prognosis.
Data indicate that microRNA miR (show MLXIP Antibodies)-214 has tumor-suppressive activity in hepatocellular carcinoma (HCC (show FAM126A Antibodies)) through inhibition of E2F2 transcription factor (E2F2), cyclin (show PCNA Antibodies)-dependent kinases CDK3 (show CDK3 Antibodies) and CDK6 (show CDK6 Antibodies).
we validated for the first time that E2F2 acts as a tumor activator in non-small cell lung carcinoma.
E2F2 loss results in increased lung metastasis in breast cancer, potentially functioning through a PTPRD (show PTPRD Antibodies) dependent mechanism.
Genomic structure, expression pattern, and functional characterization of transcription factor E2F-2 from black tiger
Findings implicate E2F-2 in regulating the expression of mitotic kinases that are adapted to perform specialized functions in nuclear condensation and enucleation of maturing erythroblasts.
Spinal cord injury-induced activation of E2F1 (show E2F1 Antibodies)-2 mediates cell cycle activation, contributing to gliopathy and neuronal/tissue loss associated with motor impairments and post-traumatic hyperesthesia.
A role for E2F1 (show E2F1 Antibodies) and E2F2 as suppressors of replicative stress in differentiating cells, and the existence of a robust E2F (show E2F1 Antibodies)-p53 (show TP53 Antibodies) regulatory axis in tissue homeostasis enabling and tumorigenesis preventing is shown.
E2F2 accumulates at sites of oxidative and UV-induced DNA damage, and interact with gammaH2AX (show H2AFX Antibodies) DNA repair factor.
E2F2 activity sustains the hepatic homeostasis of major membrane glycerolipid components while it is dispensable for storage glycerolipid balance.
Rb-deficient cells hijack and redeploy Myc (show MYC Antibodies) and E2f3 from an S-G2 (show STRN3 Antibodies) program essential for normal cell cycles to a G1-S program that re-engages ectopic cell cycles, exposing an unanticipated addiction of Rb-null cells on Myc (show MYC Antibodies).
showed that the D326V missense pRb (show PGR Antibodies) bound to E2F1 (show E2F1 Antibodies) but failed to interact with E2F2/3
E2F3 promotes while E2F2 suppresses ischemic cardiac repair through corresponding changes in endothelial cell proliferation.
The protein encoded by this gene is a member of the E2F family of transcription factors. The E2F family plays a crucial role in the control of cell cycle and action of tumor suppressor proteins and is also a target of the transforming proteins of small DNA tumor viruses. The E2F proteins contain several evolutionally conserved domains found in most members of the family. These domains include a DNA binding domain, a dimerization domain which determines interaction with the differentiation regulated transcription factor proteins (DP), a transactivation domain enriched in acidic amino acids, and a tumor suppressor protein association domain which is embedded within the transactivation domain. This protein and another 2 members, E2F1 and E2F3, have an additional cyclin binding domain. This protein binds specifically to retinoblastoma protein pRB in a cell-cycle dependent manner, and it exhibits overall 46% amino acid identity to E2F1.
, transcription factor E2F2
, E2F transcription factor 2
, hepatocyte growth factor-like protein